Results 11 to 20 of about 11,938 (207)

4-nitrobenzoate inhibits 4-hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy. [PDF]

FEBS Lett
Atovaquone is an antimalarial requiring potentiation for sufficient efficacy. We pursued strategies to enhance its activity, showing that 4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase, decreasing ubiquinone biosynthesis. Since atovaquone competes with ubiquinol in mitochondria, 4‐nitrobenzoate facilitates its action, potentiating ...
Verdaguer IB, Santos MF, Filho MM, Castro GO, Hernández A, Peres MA, Katzin AM, Crispim M.   +7 more
europepmc   +2 more sources

Atovaquone exerts its anticancer effect by inhibiting Na+/K+-ATPase ion transport in canine cancer cells [PDF]

Veterinary World, 2023
Background and Aim: New anticancer drugs are being developed to avoid the toxicity and chemoresistance of the currently available drugs. The Food and Drug Administration-approved anti-malarial drug atovaquone is known to act as a selective oxidative ...
Yousef Alharbi
doaj   +1 more source

Identification of Fis1 Interactors in Toxoplasma gondii Reveals a Novel Protein Required for Peripheral Distribution of the Mitochondrion [PDF]

, 2020
Toxoplasma gondii’s single mitochondrion is very dynamic and undergoes morphological changes throughout the parasite’s life cycle. During parasite division, the mitochondrion elongates, enters the daughter cells just prior to cytokinesis, and undergoes ...
Arrizabalaga, Gustavo, Charvat, Robert, Jacobs, Kylie   +2 more
core   +1 more source

Investigation of pre-clinical pharmacokinetic parameters of atovaquone nanosuspension prepared using a pH-based precipitation method and its pharmacodynamic properties in a novel artemisinin combination

Journal of Global Antimicrobial Resistance, 2020
Objectives: Recently, a growing resistance to antimalarial drugs such as chloroquine, sulfadoxine–pyrimethamine, artemisinin derivatives and mefloquine has been observed. The pharmacokinetic limitation of the current therapy and multi-drug resistance has
Harsha Kathpalia, Siddhesh Juvekar, Krishnapriya Mohanraj, Mrunal Apsingekar, Supriya Shidhaye   +4 more
doaj   +1 more source

Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients

EJNMMI Research, 2021
Background Tumour hypoxia promotes an aggressive tumour phenotype and enhances resistance to anticancer treatments. Following the recent observation that the mitochondrial inhibitor atovaquone increases tumour oxygenation in NSCLC, we sought to assess ...
Pauline Bourigault, Michael Skwarski, Ruth E. Macpherson, Geoff S. Higgins, Daniel R. McGowan   +4 more
doaj   +1 more source

Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation

Blood Advances, 2019
: Atovaquone, a US Food and Drug Administration–approved antiparasitic drug previously shown to reduce interleukin-6/STAT3 signaling in myeloma cells, is well tolerated, and plasma concentrations of 40 to 80 µM have been achieved with pediatric and adult
Alexandra M. Stevens, Michael Xiang, Lisa N. Heppler, Isidora Tošić, Kevin Jiang, Jaime O. Munoz, Amos S. Gaikwad, Terzah M. Horton, Xin Long, Padmini Narayanan, Elizabeth L. Seashore, Maci C. Terrell, Raushan Rashid, Michael J. Krueger, Alicia E. Mangubat-Medina, Zachary T. Ball, Pavel Sumazin, Sarah R. Walker, Yoshimasa Hamada, Seiichi Oyadomari, Michele S. Redell, David A. Frank   +21 more
doaj   +1 more source

Data on the combined effect of atovaquone, mefloquine, and 3-bromopyruvic acid against Echinococcus multilocularis protoscoleces

Data in Brief, 2022
The dataset presented here is related to a previous research article titled “Mitochondrial Complex III in Larval Stage of Echinococcus multilocularis as a Potential Chemotherapeutic Target and in vivo Efficacy of Atovaquone Against Primary Hydatid Cysts”[
Hirokazu Kouguchi, Shigehiro Enkai, Hiroyuki Matsuyama, Masahito Hidaka, Daniel Ken Inaoka, Kiyoshi Kita, Kinpei Yagi   +6 more
doaj   +1 more source

KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. [PDF]

, 2014
Preventing relapses of Plasmodium vivax malaria through a radical cure depends on use of the 8-aminoquinoline primaquine, which is associated with safety and compliance issues.
Borboa, Rachel, Campo, Brice, Chatterjee, Arnab K, Chen, Zhong, Diagana, Thierry T, Gagaring, Kerstin, Glynne, Richard J, Klooster, Els J, Kocken, Clemens HM, Kuhen, Kelli, Leroy, Didier, Luty, Adrian, McNamara, Case W, Nagle, Advait, Plouffe, David M, Remarque, Edmond J, Roland, Jason, Sauerwein, Robert, Thomas, Alan W, van Amsterdam, Sandra M, van den Berg, Alexander, van Gemert, Geert-Jan, Voorberg-van der Wel, Annemarie, Winzeler, Elizabeth A, Yeung, Bryan KS, Zeeman, Anne-Marie   +25 more
core   +1 more source

Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study

BMC Medicine, 2022
Background Individuals with a family history of colorectal cancer (CRC) are at a high risk of developing CRC. Preclinical studies suggest that the anti-malaria drug proguanil and atovaquone might play a role in preventing CRC, but population-based ...
Naiqi Zhang, Jan Sundquist, Kristina Sundquist, Jianguang Ji   +3 more
doaj   +1 more source

Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa [PDF]

, 2010
Background: The importation of malaria to non-endemic countries remains a major cause of travel-related morbidity and a leading cause of travel-related hospitalizations. Currently they are three priority medications for malaria prophylaxis to West Africa:
Widmer, Lukas L, Blank, Patricia R, Van Herck, Koen, Hatz, Christoph, Schlagenhauf, Patricia   +4 more
core   +3 more sources